Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 16 citations · 43 references
MedicineMolecular BiologyMolecular GeneticsGenomicsPharmacogeneticsPharmacogenomicsMyeloproliferative NeoplasmsNext-generation Sequencing In OncologyRelapsed DiseaseVariant InterpretationChronic Myeloid Leukemia TherapyExome SequencingGenomic Predictors Of RecurrenceMolecular RelapsePositive Predictive ValueRelapse-free SurvivalRelapsed LeukemiaTherapeutic Tyrosine Kinase Inhibitors
Chronic myeloid leukemia (CML) is a myeloproliferative disease well treated by tyrosine kinase inhibitors (TKIs). The aim was to identify genes with a predictive value for relapse-free survival after TKI cessation in CML patients. We performed whole-exome sequencing of DNA from six CML patients in long-lasting deep molecular remission. Patients were divided into two groups with relapse (n = 3) and without relapse (n = 3) after TKI discontinuation. We found variants in genes CYP1B1, ALPK2, and IRF1 in group of patients with relapse and one variant in gene PARP9 in group of patients without relapse. We verified prognostic value of the found markers in a small group of patients with TKI discontinuation and demonstrated their high sensitivity (77%), specificity (86%), positive (85%), and negative (79%) predictive values. Thus we revealed genetic variants, which are potential markers of outcome prediction in CML patients after TKI discontinuation.
43
Genetic Alterations during Colorectal-Tumor Development
Bert Vogelstein, Eric R. Fearon, Stanley R. Hamilton et al. · New England Journal of Medicine · 1988 · 6.8K citations
Predicting Deleterious Amino Acid Substitutions
Pauline C. Ng, Steven Henikoff · Genome Research · 2001 · 2.7K citations · Full text
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text